Abstract

This research proposal is to study the effects of opioids and opioid antagonists, and of prototypical and atypical antipsychotic drugs on behavior controlled by noxious stimuli and other consequent events. One major objective will be to specify the pharmacological and environmental factors responsible for the development and expression of supersensitivity to the behavioral effects of opioid antagonists. Studies will be conducted on how the development of supersensitivity is modified by the type of schedule and type of consequent event that maintains behavior, and on how developed supersensitivity alters the behavioral effects of opioids from different chemical classes. Other studies will investigate how the behavioral effects of opioid antagonists are modified by pretreatment with other drugs in supersensitive and normal subjects, and on how supersensitivity alters the antagonistic effects of opioid antagonists. Supersensitivity also will be studied in relation to the suppression of behavior by response-produced injections of opioid antagonists or by stimuli associated with injections of antagonists. A second major objective of the proposed research is to characterize the distinctive behavioral effects of prototypical and atypical antipsychotic drugs and to specify how these effects are determined by the environmental conditions that maintain or suppress behavior.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37MH007658-25
Application #
3486281
Study Section
Pharmacology I Research Subcommittee (DABR)
Project Start
1975-05-01
Project End
1992-04-30
Budget Start
1988-07-01
Budget End
1989-04-30
Support Year
25
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
Harvard University
Department
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115

  Publications

Paronis, Carol A; Bergman, Jack (2011) Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. J Pharmacol Exp Ther 336:488-95
DeWeese, Jo (2009) Changes in blood pressure and heart rate during fixed-interval responding in squirrel monkeys. J Exp Anal Behav 92:379-85
Rosenzweig-Lipson, S; Bergman, J (1994) Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys. Eur J Pharmacol 260:237-41
Yasar, S; Bergman, J (1994) Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 56:768-73
Rosenzweig-Lipson, S; Hesterberg, P; Bergman, J (1994) Observational studies of dopamine D1 and D2 agonists in squirrel monkeys. Psychopharmacology (Berl) 116:9-18
Wettstein, J G; Teeple, E S; Morse, W H (1993) Combination of buspirone and other drugs with beta-CCE in monkeys: effects on respiration and behavior. Pharmacol Biochem Behav 44:633-41
Rosenzweig-Lipson, S; Bergman, J (1993) Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys. J Pharmacol Exp Ther 267:765-75
Rosenzweig-Lipson, S; Bergman, J (1993) Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynaphthoxazine by dopamine antagonists in monkeys. J Pharmacol Exp Ther 265:1039-46
Spealman, R D; Bergman, J (1992) Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J Pharmacol Exp Ther 261:607-15
Wettstein, J G (1990) Unusual behavioral profile of alprazolam in squirrel monkeys. J Pharmacol Exp Ther 253:1070-6

Showing the most recent 10 out of 31 publications